The results of the Hallmark pathway analysis suggest that the patients with high C1orf50 expression may have suppressed immunity, but it remains unclear whether there is a patient population in Luminal breast cancer for whom immune checkpoint inhibitors, currently widely used in triple-negative breast cancer, are effective. The gene discussed is C1orf50; the disease is breast carcinoma.